Serial Measurements of Tricuspid Regurgitation Pressure Gradient by Echocardiography Predict Prognosis in Idiopathic Pulmonary Fibrosis
DOI:
https://doi.org/10.17140/PRRMOJ-3-124Keywords:
Tricuspid regurgitation pressure gradient, Idiopathic pulmonary fibrosis, echo-cardiography, Combined pulmonary fibrosis and emphysemaAbstract
Background and Objectives: Idiopathic Pulmonary Fibrosis (IPF), especially with emphysema, reportedly involved with Pulmonary Hypertension (PH). However, it is not elucidated whether pulmonary arterial pressure changes serially during the course and influence on prognosis in IPF. We examined whether serial measurements of Tricuspid Regurgitation Pressure Gradient (TRPG) by echocardiography were meaningful predictors of IPF patient survival.
Methods: We retrospectively investigated 83 IPF patients. The echocardiographic TRPG cutoff was set at 30 mmHg, and the subjects were divided into two groups: high TRPG and normal TRPG. We also evaluated the relationship between serial TRPG changes during follow-up.
Results: A total of 28 patients were included in the high TRPG group. The high TRPG group showed significantly lower %FVC and %DLco, higher A-aDO2, shorter 6-minute walk test distance, and more frequent emphysema than the normal TRPG group. The high TRPG group also had poorer survival than the normal TRPG group. A multivariate Cox proportional hazard model demonstrated that TRPG, %FVC, and A-aDO2 significantly affected patient survival. Thirty-six patients underwent echocardiography twice. At the time of the second echocardiography, 7 patients with normal TRPG at baseline (n=22) increased to a TRPG of more than 30 mmHg. These patients had significantly showed poorer survival.
Conclusions: TRPG is an independent prognostic factor in IPF. Emphysema involvement, de-creased DLco, and decreased FVC were associated with an increase in TRPG. Serial measurements of TRPG are recommended for the early detection of PH and predict prognosis in IPF patients.
References
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/ JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788-824. doi: 10.1164/rccm.2009- 040GL
Rudd RM, Prescott RJ, Chalmers JC, Johnston ID. Fibrosing alveolitis subcommittee of the research committee of the British thoracic society. British Thoracic Society study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax. 2007; 62(1): 62-66. doi: 10.1136/thx.2005.045591
Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Inci-dence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010; 137(1): 129- 137. doi: 10.1378/chest.09-1002
Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibro-sis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014; 190(7): 773-779. doi: 10.1164/rccm.201403- 0566OC
Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3): 746-752. doi: 10.1378/chest.129.3.746
Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hy-pertension in patients with idiopathic pulmonary fibrosis. Chest. 2005; 128(4): 2393-2399. doi: 10.1378/chest.128.4.2393
Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pul-monary fibrosis and emphysema: decreased survival associ-ated with severe pulmonary arterial hypertension. Chest. 2009; 136(1): 10-15. doi: 10.1378/chest.08-2306
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibro-sis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 26(4): 586-593. doi: 10.1183/09031936.05.00021005
Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009; 34(1): 1219-1263. doi: 10.1093/eurheartj/ehp297
Goto K, Arai M, Watanabe A, Hasegawa A, Nakano A, Kura-bayashi M. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pul-monary arterial hypertension. Int Heart J. 2010; 51(5): 343-347. doi: 10.1536/ihj.51.343
Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardio-graphic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167(5): 735-740. doi: 10.1164/rccm.200210-1130OC
Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmo-nary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2008; 102(9): 1305-1310. doi: 10.1016/j.rmed.2008.03.022
Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmo-nary fibrosis. Respir Med. 2009; 103(2): 180-186. doi: 10.1016/j. rmed.2008.11.012
Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed to-mography in pulmonary emphysema. Clin Radiol. 1982; 33(4): 379-387. doi: 10.1016/S0009-9260(82)80301-2
Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K. Clinical characteristics of combined pulmonary fi-brosis and emphysema. Respirology. 2010; 15(2): 265-271. doi: 10.1111/j.1440-1843.2009.01676.x
American Thoracic Society. Guidelines for the six-minute walk test. Consensus statement. Am J Respir Crit Care Med. 2002; 166:111-117. doi: 10.1164/rccm.166/1/111
Papakosta D, Pitsiou G, Daniil Z, et al. Prevalence of pulmo-nary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. Lung. 2011; 189(5): 391-399. doi: 10.1007/s00408-011-9304-5
Kimura M, Taniguchi H, Kondoh Y, et al. Pulmonary hyper-tension as a prognostic indicator at the initial evaluation in id-iopathic pulmonary fibrosis. Respiration. 2013; 85(6): 456-463. doi: 10.1159/000345221
Hamada K, Nagai S, Tanaka S, et al. Significance of pulmo-nary arterial pressure and diffusion capacity of the lung as prog-nosticators in patients with idiopathic pulmonary fibrosis. Chest. 2007; 131(3): 650-656. doi: 10.1378/chest.06-1466
Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natri-uretic peptide and exercise capacity in lung fibrosis and pulmo-nary hypertension. Am J Respir Crit Care Med. 2004; 170(4): 360-365. doi: 10.1164/rccm.200308-1142OC
Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain na-triuretic peptide is a prognostic parameter in chronic lung dis-ease. Am J Respir Crit Care Med. 2006; 173(7): 744-750. doi: 10.1164/rccm.200510-1545OC
Kinder BW, Brown KK, McCormack FX, et al. Serum sur-factant protein-A is a strong predictor of early mortality in idio-pathic pulmonary fibrosis. Chest. 2009; 135(6): 1557-1563. doi: 10.1378/chest.08-2209
Takahashi H, Fujishima T, Koba H, et al. Serum surfac-tant proteins A and D as prognostic factors in idiopathic pulmo-nary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000; 162(3 Pt 1): 1109-1114. doi: 10.1164/ajrc-cm.162.3.9910080
Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006; 11(2): 164-168. doi: 10.1111/j.1440-1843.2006.00834.x
Travis WD, Costabel U, Hansell DM, et al. An Official Amer-ican Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6): 733-748. doi: 10.1164/rccm.201308-1483ST
Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocardiographic and hemodynamic predic-tors of mortality in idiopathic pulmonary fibrosis. Chest. 2013; 144(2): 564-570. doi: 10.1378/chest.12-2298
Todd NW, Jeudy J, Lavania S, et al. Centrilobular em-physema combined with pulmonary fibrosis results in im-proved survival. Fibrogenesis Tissue Repair. 2011; 4(1): 6. doi: 10.1186/1755-1536-4-6
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
